OR WAIT null SECS
September 25, 2019
The companies have advanced their collaboration to the next stage and will continue to develop a plant-based biosimilar candidate to Roche’s Rituxan.
Under a new co-development license agreement, Boehringer Ingelheim and Inflammasome Therapeutics aim to develop novel therapies for retinal diseases.
September 23, 2019
The companies will focus on identifying peptides applicable to the affinity chromatography process used in the purification of biopharmaceuticals.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization for Bavencio (avelumab) in combination with axitinib for treating kidney cancer.
September 20, 2019
A request has been made to the CHMP by the executive director of EMA to provide guidance on how to avoid the presence of nitrosamine impurities in human medicines.
Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines.
September 18, 2019
The merger creates a combined organization with a leading position in the eClinical market.
Colorcon Ventures looks to fund promising startups in drug manufacturing, delivery, and supply chain.
September 16, 2019
The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.